Deerfield Management Company, L.P. (Series C) Vericel Corp Transaction History

Deerfield Management Company, L.P. (Series C)

$4.04 Billion
Q4 2024

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	BUY	$22.62 - $32.54 $11 Million - $15.8 Million	484,947 New	484,947 $11.3 Million
Q1 2021 May 17, 2021	SELL	$30.93 - $59.48 $2.01 Million - $3.86 Million	-64,946 Closed	0 $0
Q4 2020 Feb 16, 2021	SELL	$18.53 - $31.5 $26.4 Million - $44.9 Million	-1,425,172 Reduced 95.64%	64,946 $2.01 Million
Q3 2020 Nov 16, 2020	SELL	$14.68 - $19.12 $23 Million - $30 Million	-1,567,043 Reduced 51.26%	1,490,118 $27.6 Million
Q2 2020 Aug 14, 2020	SELL	$8.5 - $15.82 $11.8 Million - $22 Million	-1,389,948 Reduced 31.26%	3,057,161 $42.3 Million
Q1 2020 May 15, 2020	BUY	$7.25 - $19.22 $12.3 Million - $32.7 Million	1,699,546 Added 61.86%	4,447,109 $40.8 Million
Q4 2019 Feb 14, 2020	BUY	$13.77 - $19.2 $9.18 Million - $12.8 Million	666,563 Added 32.03%	2,747,563 $47.8 Million
Q3 2019 Nov 14, 2019	BUY	$14.93 - $19.83 $170,187 - $226,042	11,399 Added 0.55%	2,081,000 $31.5 Million
Q2 2019 Aug 14, 2019	BUY	$15.01 - $18.89 $5.71 Million - $7.19 Million	380,601 Added 22.53%	2,069,601 $39.1 Million
Q1 2019 May 15, 2019	SELL	$16.23 - $20.29 $33.1 Million - $41.3 Million	-2,036,900 Reduced 54.67%	1,689,000 $29.6 Million
Q4 2018 Feb 14, 2019	BUY	$10.77 - $18.44 $22.7 Million - $38.9 Million	2,108,170 Added 130.32%	3,725,900 $64.8 Million
Q3 2018 Nov 14, 2018	BUY	$9.1 - $14.8 $14.7 Million - $23.9 Million	1,617,730 New	1,617,730 $22.9 Million

Others Institutions Holding VCEL

# of Institutions

293

Shares Held

50.7M

Call Options Held

98.2K

Put Options Held

135K

View Full List

About Vericel Corp

Ticker VCEL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 47,178,000
Market Cap $2.24B
Description
Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in the United States. The company markets autologous cell therapy products comprising MACI, an autologous cellularized scaffold product for t...

More about VCEL

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Deerfield Management Company, L.P. (Series C), based on Form 13F filings with the SEC.

News

Stay updated on Deerfield Management Company, L.P. (Series C) with notifications on news.

Account